Observational studyKidney3602026
Thyroid Function with Continuous KRT: A Prospective Study.
Observational study in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Depletion of the Antioxidant Ergothioneine by Critical Illness and Continuous Renal Replacement Therapy.Kidney and dialysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
key pointsWe identify a novel consequence of continuous KRT: clearance of thyroid-stimulating hormone and thyroid hormone. Severe non-thyroidal illness syndrome occurs in most of the continuous KRT patients and is persistent during continuous KRT. Notably, no patient achieved euthyroid status during continuous KRT therapy.
backgroundAKI and ESKD requiring continuous KRT (CKRT) are associated with a high mortality rate. Solutes up to 40 kDa in size are amenable to CKRT clearance which includes thyroid-stimulating hormone (TSH; 28 kDa), free thyroxine (fT4; 0.78 kDa), and free triiodothyronine (fT3; 0.68 kDa). The effect of CKRT on TSH and thyroid hormone clearance, thyroid function, and the hypothalamic-pituitary-thyroid axis is unknown.
methodsThis prospective, single-center observational study enrolled 50 intensive care unit patients requiring CKRT and 50 control intensive care unit patients. Serum TSH, fT4, fT3, and reverse triiodothyronine were measured before and on days 1, 3, 8, and 14 after CKRT initiation and at the same time points relative to enrollment in control patients; effluent TSH, fT4, and fT3 were measured on days 1, 3, 8, and 14. Thyroid function status was adjudicated on days 1, 3, 8, and 14. Statistical analyses included employment of linear mixed modeling and time-dependent adjustments, and ANOVA with false discovery rate correction.
resultsBefore and during CKRT, CKRT patients had lower fT4 and fT3 levels compared with controls, with a higher proportion of values below the normal reference range. TSH and fT4 were detected in the CKRT effluent, indicating clearance by CKRT. Severe and persistent non-thyroidal illness syndrome (NTIS) was seen in the CKRT cohort. No patient achieved euthyroid status while receiving CKRT.
conclusionsThis is the first study to assess thyroid function and clearance of TSH and thyroid hormones during CKRT. We demonstrate that severe NTIS-characterized by low levels of fT4 and fT3-occurs in most of the CKRT patients. Furthermore, NTIS is persistent in patients receiving CKRT, which may be influenced by CKRT-mediated TSH and fT4 clearance. These novel complications may contribute to the high mortality rate observed in patients with either AKI or ESKD who receive CKRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.